Kiel

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 Diffuse large B-cell lymphoma (DLBCL)
• Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised
  2024-520302-19-00 4 Atopic dermatitis
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R … Pending
  2024-513445-37-00 5 previously untreated RT, irrespective of risk factors and disease stag
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 Idiopathic pulmonary fibrosis (IPF)
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu … Pending
  2024-517561-16-00 4 non-small cell lung cancer
• Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the ass … Pending
  2024-518835-13-00 5 Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
• A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 … Pending
  2024-519326-20-00 4 Patients with diagnosis of unresectable clinical stage III or IV metas
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 Immune system diseases
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study to Learn About the Study Medicine Called PF-08049820 in People With Eczema, an Itchy Skin Rash Pending
  2025-522965-31-00 4 Atopic Dermatitis
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral … Pending
  2025-524386-24-00 5 Head and neck cancer
• The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID? Pending
  2025-524443-12-00 4 Post Covid Syndrome (PCS)
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms

Showing 1–24 of 426 trials